Literature DB >> 9834235

Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2).

S H Kim1, E Y Choi, Y K Shin, T J Kim, D H Chung, S I Chang, N K Kim, S H Park.   

Abstract

Despite the fact that Hodgkin's and Reed-Sternberg (H-RS) cells are morphological hallmarks of Hodgkin's disease (HD), the nature of H-RS cells still remains to be resolved. Here we report that downregulation of CD99 (Mic2) leads to the generation of cells with an H-RS phenotype. IM9 and BJAB B-cell lines that were transfected with an antisense CD99 expression construct showed the morphological and immunological characteristics of H-RS cells such as multinuclearity, expression of CD15, decreased expression of major histocompatibility complex (MHC) class I and CD45RB, and deregulated secretion of cytokines. The reduced expression of CD99 was also confirmed in H-RS cells of patient's lymph nodes and three HD-derived cell lines, L428, KM-H2, and HDLM-2. Moreover, features characteristic of H-RS cells were completely abolished by forced expression of CD99 and by a constitutively active form of Rac, which functions downstream of CD99. We suggest that CD99 molecules play a crucial role in regulating functions and morphology of cells through a Rac-Rho signaling pathway and that the loss of CD99 expression is a significant molecular event to generate H-RS cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834235

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Expression of CD99 in pleomorphic carcinomas of the lung.

Authors:  Seong-Ho Yoo; Jungho Han; Tae Jin Kim; Doo Hyun Chung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter.

Authors:  Eun Kyung Lee; Ji Hye Chae; Myung-Soo Kang
Journal:  Mol Cells       Date:  2011-10-19       Impact factor: 5.034

3.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.

Authors:  F M Raaphorst; F J van Kemenade; T Blokzijl; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

4.  CD99-dependent expansion of myeloid-derived suppressor cells and attenuation of graft-versus-host disease.

Authors:  Hyo Jin Park; Dahye Byun; An Hi Lee; Ju Hyun Kim; Young Larn Ban; Masatake Araki; Kimi Araki; Ken-Ichi Yamamura; Inho Kim; Seong Hoe Park; Kyeong Cheon Jung
Journal:  Mol Cells       Date:  2012-02-15       Impact factor: 5.034

Review 5.  The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma.

Authors:  Im-Soon Lee; Seok Hyung Kim; Hyung Geun Song; Seong Hoe Park
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

6.  Interaction of CD99 with its paralog CD99L2 positively regulates CD99L2 trafficking to cell surfaces.

Authors:  Giri Nam; Young-Kwan Lee; Hye Yeong Lee; Min Jung Ma; Masatake Araki; Kimi Araki; Seungbok Lee; Im-Soon Lee; Eun Young Choi
Journal:  J Immunol       Date:  2013-10-16       Impact factor: 5.422

7.  SEPTIN2 and STATHMIN Regulate CD99-Mediated Cellular Differentiation in Hodgkin's Lymphoma.

Authors:  Wenjing Jian; Lin Zhong; Jing Wen; Yao Tang; Bo Qiu; Ziqing Wu; Jinhai Yan; Xinhua Zhou; Tong Zhao
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  CD99 Is Strongly Expressed in Basal Cells of the Normal Adult Epidermis and Some Subpopulations of Appendages: Comparison with Developing Fetal Skin.

Authors:  Gawon Choi; Jin Roh; Chan-Sik Park
Journal:  J Pathol Transl Med       Date:  2016-08-07

Review 9.  Non-Coding RNAs in Hodgkin Lymphoma.

Authors:  Anna Cordeiro; Mariano Monzó; Alfons Navarro
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

Review 10.  CD99 at the crossroads of physiology and pathology.

Authors:  Michela Pasello; Maria Cristina Manara; Katia Scotlandi
Journal:  J Cell Commun Signal       Date:  2018-01-06       Impact factor: 5.782

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.